English

YEAR-END REPORT 2016

Report this content

High growth and strong performance for Zinzino Health

Total sales revenue for the fourth quarter in 2016 totalled MSEK 149.3 and is the strongest performance ever for Zinzino AB (publ). With big investments in IT systems, new products and entrance into new markets, the growth target of 20% was exceeded upon substantially and resulted in total growth of 29% for the fourth quarter.

The Swedish market achieved more than 50% growth when compared to the same quarter last year, whilst Norway, Denmark, Finland and USA continued to show strong figures. The health product segment showed the biggest growth with an increase of 41%. The customer base continued to increase and reached over 110,000 customers, largely due to an improved website and web shop.

Commenting on the report, Dag Bergheim Pettersen, CEO of Zinzino, said” We are very pleased with growth of 29 % and surpassing our target for the fourth quarter. It feels great to be performing so well, especially considering all the improvements to our sales system, the launch of new product and the opening up of more new markets over the last year’’.  

Previous quarter  

  • Total revenue amounted to MSEK 149.3 (115.4) representing a growth in sales of 29% (-1%).
  • The product segment Health increased by 41% and amounted to MSEK to 91.2 (64.9).
  • The product segment Coffee fell slightly with 29% and amounted to MSEK 17.6 (24.9).
  • Subsidiary company Faun Pharma AS increased external sales by 139 % and amounted to MSEK 20.8 (8.7). Faun Pharma produce several Zinzino products for the health food market.
  • Gross profit amounted to MSEK 50.9 (42.5) and the gross profit margin amounted to 34.1 % (36.8%).
  • EBITDA amounted to MSEK 4.6 (3.6) with an operating margin of 3.1 % (3.2%) before depreciation.

2015-2016  

  • Total revenue amounted to MSEK 492.3 (443.8), representing a growth in sales of 11% (22%).
  • The product segment Health increased by 23% and amounted to MSEK 323.5 (263.2).
  • The product segment Coffee fell slightly with 31% and amounted to MSEK 63.3 (92.2).
  • Faun Pharma AS increased external sales by 45% that amounted to MSEK 50.5 (34.8).
  • Gross profit amounted to MSEK 167.2 (149.3) with a gross profit margin of 34.0% (33.6 %).
  • EBITDA amounted to MSEK 23.1 (25.6) and an operating margin of 4.7 % (5.8 %) before depreciation.
  • Liquid assets amounted to 23.3 (26.9) MSEK.
  • The board suggests an unchanged share dividend of 0.25 SEK/stock.

For a copy of the complete Year-End report 2016 visit www.zinzino.se

 
For more information:
Dag Bergheim Pettersen, CEO, Zinzino
Tel. +47 (0) 93 22 57 00

Pictures for publication free of charge: 
Lars Dahlberg, Tel. + 46 (0) 70-779 77 70

Certified Adviser: Erik Penser Bank

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 08.00 am on 28th February, 2017. 

 

Zinzino Nordic AB (publ.) is a direct sales company that operates throughout the EU, Norway, Iceland and North America. Zinzino markets and sells products in two product lines; Zinzino Health, with a focus on long term health, and Zinzino Coffee, consisting of espresso machines, coffee, tea and accessories.

Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Today Zinzino has 100 employees and its head office is located in Gothenburg, with additional offices in Helsinki, Riga, and in Florida, USA. Zinzino is a public company and its shares are listed on Nasdaq First North.

Zinzino has received business awards such as ‘’Superföretag 2015’’ from Veckans Affärer and was also recognized by Dagens Industri with the ‘’Gazelle’’ award in 2013.

Tags:

Zinzino Q4 2016

Subscribe

Documents & Links